Clearmind Medicine evaluates psychedelic drug for FDA breakthrough status

April 27, 2026 7:41 AM

Clearmind Medicine Inc. (NASDAQ: CMND) announced it is evaluating its lead drug candidate CMND-100 for potential FDA Breakthrough Therapy Designation ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found